580 related articles for article (PubMed ID: 19025702)
1. Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing in-patients with COPD exacerbations decreases bronchodilator costs.
Drescher GS; Carnathan BJ; Imus S; Colice GL
Respir Care; 2008 Dec; 53(12):1678-84. PubMed ID: 19025702
[TBL] [Abstract][Full Text] [Related]
2. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.
Breekveldt-Postma NS; Koerselman J; Erkens JA; Lammers JW; Herings RM
Respir Med; 2007 Jul; 101(7):1398-405. PubMed ID: 17368011
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
Baker WL; Baker EL; Coleman CI
Pharmacotherapy; 2009 Aug; 29(8):891-905. PubMed ID: 19637942
[TBL] [Abstract][Full Text] [Related]
4. Survival with tiotropium compared to long-acting Beta-2-agonists in Chronic Obstructive Pulmonary Disease.
Gershon AS; Wang L; To T; Luo J; Upshur RE
COPD; 2008 Aug; 5(4):229-34. PubMed ID: 18671148
[TBL] [Abstract][Full Text] [Related]
5. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
Lee TA; Wilke C; Joo M; Stroupe KT; Krishnan JA; Schumock GT; Pickard AS
Arch Intern Med; 2009 Aug; 169(15):1403-10. PubMed ID: 19667304
[TBL] [Abstract][Full Text] [Related]
6. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.
Chen AM; Bollmeier SG; Finnegan PM
Ann Pharmacother; 2008 Dec; 42(12):1832-42. PubMed ID: 18957624
[TBL] [Abstract][Full Text] [Related]
7. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore.
Lee KH; Phua J; Lim TK
Respir Med; 2006 Dec; 100(12):2190-6. PubMed ID: 16635566
[TBL] [Abstract][Full Text] [Related]
9. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids.
Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
Respirology; 2006 Sep; 11(5):598-602. PubMed ID: 16916333
[TBL] [Abstract][Full Text] [Related]
10. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
11. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study.
Donohue JF; Hanania NA; Ciubotaru RL; Noe L; Pasta DJ; Schaefer K; Claus R; Andrews WT; Roach J
Clin Ther; 2008; 30 Spec No():989-1002. PubMed ID: 18640474
[TBL] [Abstract][Full Text] [Related]
12. Tiotropium: a bronchodilator for chronic obstructive pulmonary disease.
Somand H; Remington TL
Ann Pharmacother; 2005 Sep; 39(9):1467-75. PubMed ID: 16030078
[TBL] [Abstract][Full Text] [Related]
13. Tiotropium in COPD patients not previously receiving maintenance respiratory medications.
Adams SG; Anzueto A; Briggs DD; Menjoge SS; Kesten S
Respir Med; 2006 Sep; 100(9):1495-503. PubMed ID: 16698259
[TBL] [Abstract][Full Text] [Related]
14. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
15. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
[TBL] [Abstract][Full Text] [Related]
16. Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.
Tashkin DP
Expert Rev Respir Med; 2010 Jun; 4(3):279-89. PubMed ID: 20524910
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of tiotropium in the prevention of exacerbations of COPD.
Anzueto A; Miravitlles M
Ther Adv Respir Dis; 2009 Jun; 3(3):103-11. PubMed ID: 19617284
[TBL] [Abstract][Full Text] [Related]
18. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
Suh DC; Lau H; La HO; Choi IS; Geba GP
Curr Med Res Opin; 2010 Feb; 26(2):297-306. PubMed ID: 19961283
[TBL] [Abstract][Full Text] [Related]
19. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy.
Dalal AA; Shah M; D'Souza AO; Crater GD
Respir Med; 2012 Jun; 106(6):829-37. PubMed ID: 22425138
[TBL] [Abstract][Full Text] [Related]
20. Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD.
Kobayashi S; Suzuki S; Niikawa H; Sugawara T; Yanai M
Respirology; 2009 Jul; 14(5):675-9. PubMed ID: 19476597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]